CarthroniX is a biopharmaceutical company focused on developing small molecule-based therapies for degenerative and aging-related diseases, including arthritis. Our novel technologies are able to preserve, repair and regenerate cartilage in joints and concurrently suppress inflammation. We are also developing completely novel solutions for idiopathic pulmonary fibrosis, skin regeneration and prevention of tissue fibrosis in the skin and musculoskeletal tissues. Our discoveries are based on science conducted by world-class researchers at iconic institutions. We are CarthroniX! We are the future!
CarthroniX received a grant from the US Department of Defense in the amount of $5.0M to cover the planning phase and Phase I/IIA “Clinical Assessment of CX-011 for Pain Relief, Increased Function, and Potential Disease-Modifying Treatment for Knee Osteoarthritis”.
CarthroniX has received its first Small Business Innovation Research (SBIR) grant from NIH to advance its Fibrosis program. Special thanks to the team at NIAMS and CarthroniX partners at USC, including Dr. Denis Evseenko. CarthroniX team looks forward to achieving the Aims in the grant and advancing this therapy to the clinic.
Boehringer Ingelheim, a global leader in animal health, and CarthroniX announced a partnership to pursue small molecule therapeutics in canine oncology. Collaboration is focused on developing small molecule-based therapies for degenerative and aging-related diseases. Small molecules could provide superior disease control.
CarthroniX completes Convertible Note financing of $2.25M. Pacira BioSciences, Inc. led the financing and was joined by existing investors. The company intends to use the financing to support the final stages of pre-clinical development of CX-011, a first-in-class small molecule injectable therapeutic designed to halt or reverse the progression of mild-to-moderate knee osteoarthritis (OA)